基于新靶点的抗真菌药物研究进展

摘要/Abstract

摘要：

侵袭性真菌感染的发病率正逐年上升。现有抗真菌药物由于抗菌谱有限、副作用大等原因,致使临床应用受限。因此,基于新靶点的抗真菌药物成为治疗真菌感染的迫切需要。近年来,抗真菌药物研究取得较大进展。其中,抑制真菌细胞壁合成的药物 (如E1210和D11-2040)、抑制蛋白激酶或蛋白磷酸酶信号通路的药物 (如KP-372-1、17-AAG、Mycograb)、靶向真菌毒力因子的单克隆抗体 (如C7、²¹³Bi-18B7、¹⁸⁸Re-18B7)、激活宿主免疫系统的疫苗等,正引起人们的关注。

关键词: 抗真菌, 靶点, 化合物, 抗体, 疫苗

Abstract:

Invasive fungal infections are devastating with increasing morbidity and substantial mortality.Unfortunately,classic antifungal agents are limited by their antifungal spectrums,adverse effects,drug-drug interactions,variable pharmacokinetics,and limit types of formulation.Therefore,novel antifungal agents are urgently needed for the treatment of serious invasive fungal infections.It is possible that antifungal agents with novel targets will provide favorable options to treat fungal infections.It has made great development in antifungal agents research recent years,and the exciting advances are represented by four clusters of antifungal candidates.The first is the novel approach of candidates that destroy fungal cell walls,like E1210 and D11-2040.The second important finding is the candidates that block protein kinases signaling pathways or protein phosphatase signaling pathways,such as KP-372-1,17-AAG,and Mycograb;The third area pertains to candidates that target fungal virulence factors,like C7,²¹³Bi-18B7,¹⁸⁸Re-18B7 and so on.The fourth is the candidates that activate the host immune system,including PEV7 and β-(Man)₃-Fba-TT.Over all,these four areas demonstrate the exciting research progress on new targets of antifungal agents.

Key words: antifungal, target, compound, antibody, vaccine

中图分类号:

R978.5

黄鑫, 刘颖, 陈思敏, 安毛毛, 姜远英. 基于新靶点的抗真菌药物研究进展[J]. 中国真菌学杂志, 2015, 10(3): 175-181.

HUANG Xin, LIU Ying, CHEN Si-min, AN Mao-mao, JIANG Yuan-ying. The research progress on new targets of antifungal candidates[J]. Chinese Journal of Mycology, 2015, 10(3): 175-181.

参考文献

[1] Sifuentes-Osornio J,Corzo-León DE,Ponce-de-León LA.Epidemiology of invasive fungal infections in Latin America
[J].Curr Fungal Infect Rep,2012,6(1):23-34.

[2] Chaffin WL.Candida albicans cell wall proteins
[J].Microbiol Mol Biol Rev,2008,72(3):495-544.

[3] Hata K,Horii T,Miyazaki M,et al.Efficacy of oral E1210,a new broad-spectrum antifungal with a novel mechanism of action,in murine models of candidiasis,aspergillosis,and fusariosis
[J].Antimicrob Agents Chemother,2011,55(10):4543-4551.

[4] Miyazaki M,Horii T,Hata K,et al.In vitro antifungal activity of E1210,a novel antifungal,against clinically important yeasts and molds
[J].Antimicrob Agents Chemother,2011,55(10):4652-4658.

[5] Pfaller MA,Duncanson F,Messer SA,et al.In vitro activity of a novel broad-spectrum antifungal,E1210,tested against Aspergillus spp.determined by CLSI and EUCAST broth microdilution methods
[J].Antimicrob Agents Chemother,2011,55(11):5155-5158.

[6] Pfaller MA,Watanabe N,Castanheira M,et al.Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida:comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods
[J].J Antimicrob Chemother,2011,66(11):2581-2584.

[7] Pfaller MA,Hata K,Jones RN,et al.In vitro activity of a novel broad-spectrum antifungal,E1210,tested against Candida spp.as determined by CLSI broth microdilution method
[J].Diagn Microbiol Infec Dis,2011,71(2):167-170.

[8] Castanheira M,Duncanson FP,Diekema DJ,et al.Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against FusariumandScedosporium species identified using molecular methods
[J].Antimicrob Agents Chemother,2012,56(1):352-357.

[9] Watanabe NA,Miyazaki M,Horii T,et al.E1210,a new broad-spectrum antifungal,suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis
[J].Antimicrob Agents Chemother,2012,56(2):960-971.

[10] Wiederhold NP,Najvar LK,Fothergill AW,et al.The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans
[J].Antimicrob Agents Chemother,2015,59(1):690-692.

[11] Kitamura A,Someya K,Okumura R,et al.In vitro antifungal activities of D11-2040,a β-1,6-glucan inhibitor,with or without currently available antifungal drugs
[J].Biol Pharm Bull,2010,33(2):192-197.

[12] Kitamura A,Someya K,Hata M,et al.Discovery of a small-molecule inhibitor of β-1,6-glucan synthesis
[J].Antimicrob Agents Chemother,2009,53(2):670-677.

[13] Baxter BK,DiDone L,Ogu D,et al.Identification,in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules
[J].ACS Chem Biol,2011,6(5):502-510.

[14] Roelants FM,Torrance PD,Thorner J.Differential roles of PDK1-and PDK2-phosphorylation sites in the yeast AGC kinases Ypk1,Pkc1 and Sch9
[J].Microbiology,2004,150(10):3289-3304.

[15] Zeng Z,Samudio IJ,Zhang W,et al.Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia
[J].Cancer Res,2006,66(7):3737-3746.

[16] Cowen LE,Singh SD,Khler JR,et al.Harnessing Hsp90 function as a powerful,broadly effective therapeutic strategy for fungal infectious disease
[J].Proc Natl Acad Sci U S A,2009,106(8):2818-2823.

[17] Cowen LE.The evolution of fungal drug resistance:modulating the trajectory from genotype to phenotype
[J].Nat RevMicrobiol,2008,6(3):187-198.

[18] Blum G,Kainzner B,Grif K,et al.In vitro and in vivo role of heat shock protein 90 in amphotericin B resistance of Aspergillus terreus
[J].Clin Microbiol Infect,2013,19(1):50-55.

[19] Kamal A,Thao L,Sensintaffar J,et al.A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
[J].Nature,2003,425(6956):407-410.

[20] Gao J,Xiao S,Liu X,et al.Inhibition of HSP90 attenuates porcine reproductive and respiratory syndrome virus production in vitro
[J].Virol J,2014,11(1):17.

[21] Pachl J,Svoboda P,Jacobs F,et al.A randomized,blinded,multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis
[J].Clin Infect Dis,2006,42(10):1404-1413.

[22] Louie A,Stein DS,Zack JZ,et al.Dose range evaluation ofMycograb C28Y variant,a human recombinant antibody fragment to heat shock protein 90,in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis
[J].Antimicrob Agents Chemother,2011,55(7):3295-3304.

[23] Matthews RC,Rigg G,Hodgetts S,et al.Preclinical assessment of the efficacy of mycograb,a human recombinant antibody against fungal HSP90
[J].Antimicrob Agents Chemother,2003,47(7):2208-2216.

[24] Moragues MD,Omaetxebarria MJ,Elguezabal N,et al.A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C.albicans activities
[J].Infect Immun,2003,71(9):5273-5279.

[25] Sevilla MJ,Robledo B,Rementeria A,et al.A fungicidal monoclonal antibody protects against murine invasive candidiasis
[J].Infect Immun,2006,74(5):3042-3045.

[26] Brena S,Omaetxebarría MJ,Elguezabal N,et al.Fungicidal monoclonal antibody C7 binds to Candida albicans Als3
[J].Infect Immun,2007,75(7):3680-3682.

[27] Brena S,Cabezas-Olcoz J,Moragues MD,et al.Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans
[J].Antimicrob Agents Chemother,2011,55(7):3156-3163.

[28] Dadachova E,Nakouzi A,Bryan RA,et al.Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection
[J].Proc Natl Acad Sci U S A,2003,100(19):10942-10947.

[29] Bryan RA,Jiang Z,Howell RC,et al.Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection
[J].J Infect Dis,2010,202(4):633-637.

[30] Jiang Z,Bryan RA,Morgenstern A,et al.Treatment of early and establishedCryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice
[J].Antimicrob Agents Chemother,2012,56(1):552-554.

[31] Larsen RA,Pappas PG,Perfect J,et al.Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis
[J].Antimicrob Agents Chemother,2005,49(3):952-958.

[32] DeBernardis F,Amacker M,Arancia S,et al.A virosomal vaccine against candidal vaginitis:immunogenicity,efficacy and safety profile in animal models
[J].Vaccine,2012,30(30):4490-4498.

[33] Xin H,Cartmell J,Bailey JJ,et al.Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis
[J].PloS One,2012,7(4):e35106.

[34] Quan H,Cao YY,Xu Z,et al.Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole
[J].Antimicrob Agents Chemother,2006,50(3):1096-1099.

[35] 权华.小檗碱与氟康唑协同抗耐药白念珠菌的作用及作用机制研究
[D].上海:第二军医大学,2006.

[36] Xu Y,Wang Y,Yan L,et al.Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans:endogenous ROS augmentation
[J].J Proteome Res,2009,8(11):5296-5304.

[37] 许懿.小檗碱与氟康唑协同抗耐药白念珠菌的作用机制研究
[D].上海:第二军医大学,2010.

[38] Gallo-Ebert C,Donigan M,Stroke IL,et al.Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factor
[J].Antimicrob Agents Chemother,2014,58(1):258-266.

[39] Hata M,Ishii Y,Watanabe E,et al.Inhibition of ergosterol synthesis by novel antifungal compounds targeting C-14 reductase
[J].Med Mycol,2010,48(4):613-621.

[40] Xu D,Ondeyka J,Harris GH,et al.Isolation,structure,and biological activities of fellutamides C and D from an undescribed Metulocladosporiella (chaetothyriales) using the genome-wide Candida albicans fitness test
[J].J Nat Prod,2011,74(8):1721-1730.

[41] Rock FL,Mao W,Yaremchuk A,et al.An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site
[J].Science,2007,316(5832):1759-1761.